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 Study Management
 
 
All questions concerning this protocol should be sent via e-mail to 
 uegere@mrc.gm.  
 
For Questions About Study Subjects, The Schedule Of Events, Case Report Forms, 
Entering Waivers For Randomisation/Registration Exemptions, Transfers, And 
Delinquencies, And Other Data Management Issues, the Project Data Manager will 
respond: 
 
 
  Send an e-mail message to uegere@mrc.gm or phill@mrc.gm  
 Include the subject ID  
   Give a detailed description of the question 
 
For Adverse Events Questions: 
 
   Send an e-mail message to uegere@mrc.gm 
   Call MRC ext 441 
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Title: Community Randomised Controlled Trial to Assess the 
Impact of Vaccination with a Pneumococcal Conjugate 
Vaccine on Nasopharyngeal Carriage of Pneumococci in 
The Gambia 
Short title Sibanor Vaccine Trial 
Phase: IV 
Population: Approximately 6000 residents of 21 Gambian villages for 
vaccination 
Subsamples of 1250 subjects for evaluation  antigenic and 
molecular characteristics of pneumococci with a 
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Products or 
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Objectives: 
 
1. To determine  the impact of immunisation of a whole 
community with Prevenar on nasopharyngeal carriage of 
pneumococci. 
2. To determine the effects of vaccination on the 
prevalence, density, duration and rate of acquisition of 
nasopharyngeal colonisation with pneumococci of vaccine 
serotype and of non-vaccine serotype.  
3. To determine changes in the antigenic and molecular 
characteristics of pneumococci obtained from the 
nasopharynx of vaccinated and control subjects. 
Description of Study 
Design: 
This schematic should provide an overview of the study 
design, including study arms, sample size and schedule of 
interventions (e.g. vaccine administration), if applicable; a 
detailed schematic describing all visits and assessments 
(schedule of events) will be included in Appendix A. 
Estimated Time to 
Complete Enrolment: 
3 months 
 
 
Version 4: August 2006 7 
 
 
1.0 INTRODUCTION 
 
1.1 Background 
 
The prevention of pneumococcal disease in young children is a major, international public 
health priority. Acute lower respiratory tract infections (ALRI) are responsible for about 4 
million deaths a year in children; the majority of these deaths occur in the developing world1. 
Streptococcus pneumoniae is the most important cause of severe ALRI in children and the 
likely cause of many of these deaths2. In addition S. pneumoniae is a major cause of 
meningitis and otitis media3.  Susceptibility to pneumococcal infection is increased by HIV 
infection and the incidence of pneumococcal infection in children is increasing in sub-Saharan 
Africa4. Asymptomatic nasopharyngeal carriage of pneumococci is common in many 
developing countries, where colonisation of the nasopharynx with pneumococci commences 
shortly after birth5 and, by the age of two years, almost all children are carriers6,7. Carriage 
rates remain relatively high in older children and in adults7, who may be an important source 
of pneumococcal infection in young children.  
 
Studies undertaken in a number of developing countries have shown that mortality from 
pneumonia can be reduced significantly by active case detection and treatment of children 
with an ALRI with an antibiotic8. However, such programmes are difficult to sustain and they 
are threatened by the rapid spread of pneumococci that are resistant to widely used 
antibiotics such as co-trimoxaxole and penicillin9. The success of an Haemophilus influenzae 
type b (Hib) polysaccharide/protein conjugate vaccine in reducing the overall incidence of 
radiological pneumonia in children in The Gambia and in Chile10,11 suggests that an effective 
pneumococcal vaccine would be even more effective. 
 
Pneumococcal polysaccharide vaccines are effective in preventing invasive pneumococcal 
disease in immunocompetent adults12 but their ability to prevent pneumonia is uncertain. 13    
They are poorly immunogenic in young children14 and have little effect on the incidence of 
otitis media or nasopharyngeal carriage15,16. Thus, it was surprising that a 23-valent 
pneumococcal polysaccharide vaccine reduced mortality from pneumonia in children in Papua 
New Guinea, even in children under the age of two years17.  However, this study has not 
been repeated and attention is now being directed to polysaccharide/protein conjugate 
vaccines. Pneumococcal conjugate vaccines are immunogenic in infants and   induce 
immunological memory. Following a series of pilot studies, which demonstrated the safety 
and immunogenicity of pneumococcal conjugate vaccines when given during the first six 
months of life18, a number of large-scale efficacy trials have been undertaken. In California, a 
seven-valent pneumococcal conjugate vaccine given to infants at the ages of 2, 3 and 4 
months19 reduced the incidence of invasive pneumococcal disease caused by pneumococci of 
vaccine serotype by over 90%, the incidence of radiological pneumonia by 33% and the 
overall incidence of otitis media by 7%. A large, cluster-randomised trial of a seven-valent 
pneumococcal conjugate vaccine in Navajo and White Mountain Apache children showed a 
77% reduction in the incidence of invasive pneumococcal disease in vaccinated children but 
no significant effect on the incidence of pneumonia. 20 In contrast, in South Africa significant 
protection against both invasive pneumococcal disease (vaccine efficacy 83% [95% CI 
39.97]) and pneumonia (vaccine efficacy 20% [95% CI 2,35]) was observed among HIV 
negative children immunised with a nine-valent vaccine. Protection was less in HIV positive 
children. 21 In Finland, a seven-valent pneumococcal conjugate vaccine reduced the incidence 
of serotype specific otitis media by 57%22.   In The Gambia a large trial involving17,400 
infants given three doses of a nine-valent conjugate or control vaccine at the ages of 2, 3 and 
4 months has recently been completed.  The pneumococcal conjugate vaccine gave 
protective efficacies of 37% against radiological pneumonia and 77% against invasive 
pneumococcal disease caused by vaccine serotypes. In addition, the vaccine reduced 
morbidity and mortality among vaccinated children by 15% and 16% respectively despite   
Version 4: August 2006 8 
preventing only 50% of culture- proven pneumococcal disease23. The results of the Gambian 
trial highlight both the potential value of using existing conjugate vaccines in The Gambia and 
elsewhere and the need for additional research on pneumococcal disease prevention. A 
further trial is being conducted in the Philippines with an eleven-valent vaccine and will be 
completed at the end of this year.   
 
On the basis of the results obtained in California, the seven-valent pneumococcal conjugate 
vaccine Prevenar R produced by Wyeth Lederle was introduced into routine use in the United 
States in 2000.  The results have been dramatic; not only has invasive pneumococcal disease 
almost disappeared in the vaccinated paediatric population but the incidence of invasive 
pneumococcal disease has fallen markedly in the elderly and in young adults, 24 presumably 
because of a reduction in the spread of pneumococci of vaccine type (VT) from vaccinated 
infants.  This hypothesis is supported by the results of nasopharyngeal carriage studies, 
which have shown a reduction in the prevalence of nasopharyngeal carriage with 
pneumococci of VT in contacts of vaccinated infants. 25 
 
A reduction in the prevalence of nasopharyngeal carriage of pneumococci of VT was found in 
Gambian infants immunised with a five-valent pneumococcal conjugate vaccine during the 
first few months of life and then re-immunised with a 23-valent pneumococcal polysaccharide 
vaccine at the age of two years26. However, this was accompanied by an increase in the 
carriage rate of pneumococci of non-vaccine type (NVT), the first time that this phenomenon 
was shown, and the overall prevalence of pneumococcal carriage in vaccinated children was 
little changed.  Children in this study had very high antibody concentrations at the time that 
nasopharyngeal swabs were collected because of their booster immunisation.  A study of 
Gambian children one and four months after completion of a primary course of vaccination 
with a nine-valent conjugate vaccine at the ages of 2, 3 and 4 months showed a similar trend 
towards the replacement of pneumococci of vaccine serotype with those of non-vaccine 
serotype27 but the effect was not as marked as in the initial study, perhaps because these 
children had lower antibody concentrations. An initial study in Israel did not show serotype 
replacement28 but subsequent studies done in South Africa and in Israel have done so 29,30In 
the second Israeli study, which was undertaken in children attending day care centres, 
pneumococci of NVT were found infrequently in very young children and remained 
uncommon in non-vaccinated children. However, in vaccinated children the proportion of NVT 
pneumococci relative to those of VT isolated from the nasopharynx increased gradually with 
age and, by the age of three years, NVT pneumococci predominated 30. In American Indians, 
while the reduction in the carriage of VT pneumococci was similar across all ages after 
vaccination, the carriage of   NVT pneumococci was more marked in adults, accounting for an 
increased in the overall carriage rate 20.   Subsequently, several further studies have shown 
replacement of VT pneumococci by those of non-vaccine serotypes in the nasopharynx of 
vaccinated children.31 Because high levels of antibiotic resistance are found most frequently 
among pneumococci of vaccine serotype, vaccination with pneumococcal conjugate vaccines 
has led to a reduction in the prevalence of antibiotic resistant pneumocococi in vaccinated 
children 31 and, in the United States, introduction of infant immunisation with a pneumococcal 
conjugate vaccine has had an impact on the overall prevalence of antibiotic resistant 
pneumococci.32 Thus, there are clear indications that serotype replacement as a consequence 
of vaccination can have indirect beneficial effects.    Could serotype replacement in the 
nasopharynx also have undesirable consequences? 
    
The non-vaccine serotypes of pneumococci found most frequently in vaccinated children, for 
example serotypes 3, 7F, 8, 12F, 45 and 46, are capable of causing invasive disease in 
experimental animals and, in the absence of vaccination, occasionally caused invasive disease 
in man. For this reason concerns were expressed shortly after the replacement effect was 
first observed that there was a risk that widespread introduction of a vaccine directed against 
only a limited number of serotypes might result in an increase in the incidence of invasive 
disease caused by pneumococci of NVT. 33 Initial experience in California was reassuring but, 
in 2001, Finnish scientists reported an increase of 37% in the incidence of otitis media caused 
by pneumococci of NVT in children who had received a pneumococcal conjugate vaccine. 22 
Version 4: August 2006 9 
However, until recently there was no evidence for an increase in the incidence of invasive 
pneumococcal disease caused by pneumococci of NVT in vaccinated populations. Overall 
experience in the United States since the introduction of Prevenar R has been reassuring but a 
small increase in the incidence of invasive disease caused by pneumococci of NVT is now 
being seen in the paediatric population.   Numbers of cases are still very small and the overall 
benefit of vaccination is still overwhelming. 34 However, the recent finding of a marked and 
statistically significant increase in the incidence of invasive pneumococcal disease due to 
pneumococci of NVT among HIV positive subjects in the USA, 35 the effect being especially 
marked in females, is a matter of considerable   concern, especially for developing countries 
where the prevalence of HIV infection is high and pneumococcal disease rampant. 
 
The mechanism of serotype replacement in the nasopharynx is not fully understood. It is 
possible that initially the immune response induced by vaccination provides a selective 
advantage to pneumococci of NVT present in a mixed population of pneumococci in which 
they had previously been suppressed.  Subsequently, high antibody levels may prevent 
colonisation by VT pneumococci.  In the presence of high antibody concentrations against 
selected capsular polysaccharides, pneumoccal clones, which have other advantageous 
survival characteristics, may undergo capsular switching to a non-vaccine serotype. 36   
 
The pneumococcal conjugate vaccine trial recently completed in The Gambia employed a 
nine-valent conjugate vaccine which includes serotypes 1 and 5 conjugates that are not 
present in Prevenar R. Recent studies from Israel have shown that invasive infections caused 
by pneumococci belonging to these serotypes are especially severe. 37 Unfortunately, 
development of the nine-valent vaccine used in The Gambian trial has been stopped and, 
although at least one other multiple valent vaccine is being developed, the only vaccine likely 
to be available for routine use for a number of years is seven-valent Prevenar R.  In the USA 
where a large fall in vaccine-type invasive disease has been observed following the 
introduction of Prevenar R small increases in non-vaccine type invasive disease are being 
recorded even among unvaccinated populations but overall the effect on health is still 
positive. 
 
1.2 Rationale 
 
In The Gambia and other developing countries where children acquire pneumococci at a very 
early age, where the prevalence of colonization and the incidence of invasive disease are high 
and where the dynamics of transmission differ from the United States, it is unclear what 
impact the widespread use of pneumococcal conjugate vaccines will have on transmission 
between vaccinated and unvaccinated populations. Therefore, a study of the epidemiology of 
pneumococcal carriage has started in 21 rural Gambian villages to examine the dynamics of 
pneumococcal carriage and transmission. The main objective of this study is the evaluation of 
the effects of pneumococcal vaccination on carriage of pneumococci, particularly serotypes 1 
and 5, using a community randomised approach. Although pneumococci of serotypes 1 or 5 
are important causes of invasive disease in The Gambia, and many other developing 
countries, they are found infrequently in the nasopharynx. Could introduction of a seven-
valent vaccine enhance their ability to establish themselves in the nasopharynx and 
subsequently to cause invasive disease?  Although the introduction of a seven valent vaccine 
into communities where type 1 and type 5 pneumococcal disease is common will almost 
certainly result in a reduction in the overall incidence of invasive pneumococccal disease an 
increase in the incidence of invasive disease caused by these virulent pneumococci could 
detract from its overall public health benefit.   
 
For these reasons we believe that it is essential to determine whether the introduction of 
Prevenar R into a community where type 1 and type 5 pneumococci are important causes of 
invasive disease will result in an increase in the nasopharyngeal carriage rate of these and 
other NVT pneumococci. In order to study the effects of maximum immune pressure of the 
kind that will be seen only several years after the introduction of a pneumoocccal conjugate 
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vaccine into the infant immunisation programme we propose to study the effects of 
vaccination of a whole community as well as that of vaccinating just the infant population.  
 
1.3 Potential Risks and Benefits 
 
Prevnar has not been formally licensed for use in adults, although other studies have given 
this vaccine to adults. Secondly it is possible that serotype replacement will occur and this 
could ultimately lead to increased carriage of some pathogenic serotypes in the nasopharynx. 
 
It is likely that some individuals who might otherwise have developed invasive pneumococcal 
disease will not do so as a benefit of receiving this vaccine. Furthermore, because of the 
involvement of MRC in the villages, there may well be a health benefit for the participants 
involved in the study. 
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1.4 Study Design 
 
This study is a single-blind placebo-controlled community randomized trial. All residents 
of selected 21 Gambian villages are eligible including those born during the study.  
 
All children of the trial community between 2 months of age up to the age of 30 months 
will receive the seven-valent pneumococcal conjugate vaccine (PCV): 
 
• Subjects born during the study will receive three doses of the vaccine to be given 
monthly at the ages of 2, 3 and 4 months.  
• Subjects between the age of 2 and 11 months will receive three doses of the vaccine 
to be given monthly  
• Children aged between 12 and 30 months will receive two doses at monthly intervals.  
 
The 21 villages will be randomly assigned to one group of 10 villages and one group of 
11 villages according the randomisation SOP. All subjects above the age of 30 months will 
receive either one dose of PCV or one dose of a meningococcal polysaccharide C 
conjugate vaccine. The vaccination campaign will be village by village according to an 
SOP.Because of vaccine pre-labelling differences, nurse field workers administrating 
vaccine will be able to tell which vaccine they are giving. The field team will not 
communicate the vaccine allocation to other parties. Biological samples will have unique 
identifiers and will show no information regarding the vaccine received or the 
participants. Safety of vaccination will be monitored by nurse fieldworkers and study 
clinician according to an SOP. 
 
3, 12 and 24 months after the first vaccination, cross-sectional surveys will be conducted. 
The sample for each survey will be obtained through a random sampling method that 
ensures coverage of all age groups and all villages. This will be described in detail in an 
SOP. Each subject will have an NPS taken. 5ml blood and saliva specimens will be 
obtained from 200 subjects, selected according to a corresponding SOP before 
vaccination and then at the 3, 12 and 24 month time-points. The selected subjects will be 
distributed across the study villages stratified by age to ensure that 50 come from 
children in the age range 30 months to 5 years, 50 from children 6 to 15 years, 100 from 
those aged >15  years. 
 
NPS will be collected from all children born in the population during the study period. An 
NPS will be collected as soon as possible after birth and then at weekly intervals until the 
first dose of vaccine at 2 months. 
 
One hundred and twenty children 31-59 months of age, 130 6 to 15 years old and 180 
adults >15 years, will be selected randomly (according to an SOP). NPS will be obtained 
monthly from these subjects for 6 months and then 3 monthly until the end of the 24 
months followup. 
 
2.0 STUDY OBJECTIVES  
 
The study objectives are:   
 
• To determine the impact of immunisation of a whole community with a pneumococcal 
polysaccharide/protein conjugate vaccine on nasopharyngeal carriage of 
pneumococci.   
 
• To determine the effects of vaccination on the prevalence, density, duration and rate 
of acquisition of nasopharyngeal colonisation with pneumococci of vaccine serotype 
and of non-vaccine serotype.  
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• To determine changes in the antigenic and molecular characteristics of pneumococci 
obtained from the nasopharynx of vaccinated and control subjects. 
 
 3.0 SELECTION AND ENROLLMENT OF SUBJECTS 
 
3.1 Inclusion Criteria 
 
• Resident of one of twenty one Gambian villages  
  
3.2 Exclusion criteria 
 
• Failure of the family/subject to give consent  
• non-residence in the villages,  
• declared intent of the family/subject to leave the study area permanently within the 
following 3 months  
• Previous exposure to a conjugate pneumococcal vaccine  
 
A record will be kept of subjects who are excluded and the reason for their exclusion will 
be noted on a form.  
 
3.3 Enrollment Procedures 
 
Subjects will be recruited from twenty-one Gambian villages.  The purpose of the study will 
be described at meetings with village elders and other members of the village and what it 
involves for participants. Before enrolling individual members of the villages the nature of the 
trial will be fully explained including the treatment, observation details, spectrum of likely side 
effects, follow-up details and extent of collection of Nasopharyngeal swabs (NPS), saliva and 
blood sampling.  
 
3.4 Substudies  
 
Sub studies will take place; these will be all covered in revised consent forms, once approved. 
 
3.5 Co-enrollment Guidelines:   
 
As is MRC policy, study subjects are encouraged not to be involved in other studies.  
 
4.0 CLINICAL AND LABORATORY EVALUATIONS 
 
4.1 Pre-entry/Entry Evaluations 
 
4.11 Screening 
 
Details of the study will be carefully discussed with the subjects, who will be asked to read, or 
will be read to, and sign (or thumb-print) an informed consent form prior to any study-related 
evaluations being performed. Translations into the local languages will be provided. The 
subjects that agree to enroll and have signed consent documentation will be enrolled for the 
study.  
 
4.12 Entry 
 
Subjects will be excluded based on the criteria enumerated above (Section 3.2).  
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  4.2 Evaluations During study   
 
4.2.1 Screening at the villages 
 
• Inclusion/exclusion criteria will be checked. 
• Written informed consent will be obtained. 
• Subject Exclusion Form will be filled by the field supervisor for all subjects excluded 
from the study 
• A nurse field worker will fill the  Subject Status Form  for all subjects recruited  
• Nurse field workers will administer conjugate pneumococcal vaccine to all children up 
to the age of 30 months.  
• In group 1 villages, subjects  older than 30 months  will receive one dose of 
conjugate pneumococcal  and  their equivalent in group 2 villages will receive  one 
dose of the meningococcal polysaccharide C conjugate vaccine.  
• Vaccine ID will be included on subjects identity card 
• All subjects will be asked to report all health related complaints to the field team.  
• 5ml blood and saliva specimen will be obtained from 200 selected subjects following 
the corresponding SOP. 
• Specimens will be put in cool boxes and transferred to the MRC microbiology 
laboratory on the same day as collection. 
• For any specimen, if an individual refuses, we will select the next person on the list 
supplied by the data room. For those who are travelled we will try and capture them 
for sampling but after 2 weeks if unsuccessful, will sample the next person on the 
list. 
  
4.21 Scheduled follow-up 
 
Infants aged between 2 and 11 months will receive two additional doses of the 
pneumococcal conjugate vaccine (PCV) at monthly intervals. 
Children aged between 12 and 30 months will receive a second dose of PCV a month 
after the initial dose.  
 
At three, twelve and twenty-four months after the scheduled round of vaccination, 
nasopharyngeal swabs will be collected from approximately 1,250 subjects, ensuring 
coverage of each age group and all villages in the cross-sectional survey. These subjects 
will be selected randomly as described in section 1.4 and separate randomisation 
procedures will be undertaken for each survey; subjects included in a previous survey will 
not be excluded.  5ml blood and saliva specimens will be obtained from 200 selected 
subjects as described in section 1.4.  
 
NPS will be collected weekly from all new births into all the villages until the age of 2 
months when they receive the first doses of the pneumococcal conjugate vaccine 
 
NPS will be collected monthly from 430  selected subjects as described in section 1.4.  
 
All new births into the twenty-one villages will receive three doses of pneumococcal 
conjugate vaccine at monthly intervals from the age of two months. 
 
In the lifetime of the study, new settlers in the villages will be identified and recruited for 
the study. The same vaccination schedule will apply.  
 
All laboratory procedures will be described in SOPs. 
 
 4.3 Subjects who prematurely discontinue the study 
    
Version 4: August 2006 15 
Subjects, who leave the study at any time, may do so without repercussions. They may still 
access medical care provided by the study team, and will not be turned away. 
 
5.0 DATA COLLECTION AND MONITORING AND ADVERSE 
EXPERIENCE REPORTING 
 
5.1 Records to Be Kept 
 
A regulatory folder and a protocol deviations folder will be established. 
 
All filled in paper forms will be filed in securely by the data manager. Individual medical 
records will be filed together. All electronically stored data will be stored securely and backed 
up by the data manager.   
 
5.2 Role of Data Management  
 
The Data manager will be responsible for receiving, entering, cleaning, querying, analysing, 
and storing the data, which accrues from the study. He will generate queries to be addressed 
by the investigators and will be responsible for linking the paper and electronic data from the 
field and the clinic with the paper and electronic laboratory data from the immunology, 
microbiology, haematology and molecular biology  laboratories. 
 
5.4 Adverse events reporting  
 
Everyone vaccinated will be requested to report untoward events to the study team. Adverse 
events will be recorded as observed by the Investigators or as volunteered by the subject or 
his/her parent/guardian. Full details will be documented in the CRF whether or not the 
Investigator or his deputies consider the event to be related to the trial substance.   
 
Serious adverse events (SAEs) that occur during the study or within six months of the 
vaccinations will be notified immediately by telephone by the principal investigator to the 
study Safety Monitor. All SAEs identified will then be reported jointly by the research clinician 
and P. Hill to the Principal investigator and the study Safety Mmonitor as well as to Wyeth, 
the vaccine manufacturer, accordingly. 
 
Serious adverse events are defined as an event that:  
 
o results in death; 
o is life-threatening (i.e., the subject was at risk of death at the time of the event);  
o requires or prolongs in-patient hospitalisation;  
o results in persistent or significant disability/incapacity;  
o is a congenital anomaly/birth defect.  
 
Minimum details to be given in a telephone report are: 
 
o Name of reporting doctor and contact telephone number.  
o Study number.  
o Nature of adverse event.  
o Subject details (number, initials, sex, date of birth, weight and age). 
o Date and time of event.  
o Drug history.  
o Other relevant history.  
o Outcome.  
o Causality.  
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The event will be documented on the SAE page of the CRF and reported as appropriate.  
After the ethics committee’s response to the SAE is received, the Principal Investigator and 
Clinical Monitor will meet to determine the future plan for the study, which could involve 
amending the protocol, discontinuing the administration of the vaccine, or continuing 
unchanged for the other volunteers.  
 
6.0 STATISTICAL CONSIDERATIONS 
 
6.1 General Design Issues 
 
Villages will be randomly assigned to a study group.  A computer-generated list of 
random numbers will be used to assign villages to PCV group (Group 1) or Mening C 
group (Group 2). Nurse field workers will administer the vaccines.   
 
6.2 Outcomes of interest 
 
6.21 Impact on carriage 
 
(a) Differences in the prevalence of nasopharyngeal carriage of pneumococci of vaccine 
or of non-vaccine serotype in study villages after vaccination in the cross-sectional 
samples.  Differences in the prevalence of carriage with serotype 1 and serotype 5 
pneumococci will be of particular importance. 
 
(b)  Acquisition rates of nasopharyngeal carriage in newborns resident in vaccinated or 
control villages. 
 
(c) Rate of capsular switching in villages where community wide pneumococcal 
conjugate vaccination has been introduced, compared to those receiving placebo. 
 
6.22  Pneumococcal IgG and IgA in serum and saliva  
 
This will be determined yes/no antibody assay result, and compared to the carriage 
results. 
 
6.3 Sample Size and Accrual 
 
The baseline survey showed that the prevalence of nasopharyngeal carriage with 
pneumococci of the seven valent vaccine serotype was about 40% in infants up to the age of 
2.5 months (the age when the first dose of pneumococcal conjugate vaccine will be given) 
and 30% in those aged 30 months or more. The coefficient of variation between villages was 
0.3.  Based on these assumptions and assuming that 50 subjects are studied in each village 
the trial will have over 90% power with a type 1 error of 5% to detect a 50% reduction in the 
overall prevalence of pneumococci of vaccine serotype in those over the age of 30 months 
(prevalence 30% to 15%) and a similar power to detect a 50% reduction in the colonisation 
of infants with pneumococci of vaccine type before the age of 2 months (prevalence reduced 
from 40% to 20%. The prevalence of type 1 and type 5 carriage was very low in the initial 
survey so the study is not specifically powered to detect an increase in carriage with 
pneumococci of these serotypes but it would detect this if the effect was marked.  
 
6.4 Monitoring and Analysis 
 
The MRC Clinical Trials monitor will be responsible for monitoring the trial. This will include 
site visits to confirming the existence of the appropriate documents in the regulatory folder 
and of source documents for all required data. She will also assess the accuracy and 
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completeness of the CRF entries and other records against each other and their consistency 
with the source documents. 
 
The data manager will be responsible for data entry, data cleaning and for initial analysis 
of the results. The main analyses will be descriptive and comparative.  
 
7.0 HUMAN SUBJECTS 
 
7.1 Institutional Review Board (IRB) Review and Informed Consent 
 
Approval for the study has been given by the joint Gambia government/MRC ethics 
committee. Written informed consent will be obtained from the subject (or parent, legal 
guardian, or person with power of attorney for subjects who cannot consent for themselves, 
such as, those below the legal age).  The subject's assent will also be obtained if he or she is 
able to understand the nature, significance and risks associated with the study.  The informed 
consent will describe the purpose of the study, the procedures to be followed, and the risks 
and benefits of participation.   A copy of the consent form will be given to the subject (or 
parent or legal guardian). 
 
7.2 Subject Confidentiality 
 
All records will be kept in a secure place. All data on computer files will have restricted 
access. Clinical information will not be released without written permission of the subject, 
except as necessary for monitoring. 
  
 7.3 Data and Safety Management Board (DSMB) 
 
A data and safety management board has been constituted for the trial and a schedule for 
meetings will be agreed to. DSMB includes the following people: Dr Anthony Scott (Kilifi, 
Kenya), Dr Ayo Palmer (Banjul), Dr Derrick Crook (Oxford University) and Dr Dongmei Liu 
(London School of Hygiene and Tropical Medicine).  A clinical safety monitor will be selected 
and a programme of trial monitoring will be set up for the trial.  
 
7.4 Study Discontinuation 
 
The MRC SCC or the joint Gambian government/MRC ethics committee may discontinue the 
study after the appropriate recommendation by DSMB.  
 
8.0 PLANS FOR DISTRIBUTION OF RESEARCH FINDINGS TO STUDY 
COMMUNITY  
  
Written annual progress reports of the trial will be produced. At the end of the study, a 
research report of the methods, detailed results, and brief conclusions will be prepared for 
distribution to the collaborators. A simplified lay document will be made available to study 
subjects. 
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9.0 BIOHAZARD CONTAINMENT 
 
As the transmission of HIV and other blood-borne pathogens can occur through contact with 
contaminated needles, blood, and blood products, appropriate blood and secretion 
precautions will be employed by all personnel in the drawing of blood and shipping and 
handling of all specimens for this study, according to the MRC safety manual. 
Version 4: August 2006 19 
Appendices 
 
GAMBIAN COMMUNITY PNEUMOCOCCAL CONJUGATE VACCINE 
TRIAL-  
CONSENT PROCEDURE 
 
1. The project investigators will hold discussions with village heads and elders in villages in 
the study area to determine if they are interested in participating in the study. 
 
2. If village elders are encouraging, village meetings will be held, which will be open to the 
whole community.  At these meetings the nature of the trial and what it involves for the 
village will be discussed.  General consent for a village to join the trial will be sought at 
the meeting and if this is given, this will be documented formally. 
 
3. In villages that agree to join the trial, the head of each compound will be visited. The 
nature of the trial and what this will involve for his household will be explained by a 
trained field assistant and an opportunity will be given to ask questions.  If the compound 
head wants his household to join the trial, information sheets will be provided and 
explained after which he/she will be asked to sign a consent form (Consent form 1). 
 
4. At the time of vaccination, study individuals or the guardians of small children will be 
asked for their consent to vaccination. The fact that the respondent gave permission will 
be recorded on a special form by the field assistant who asks for permission  
 
5. Whenever a nasopharyngeal swab or blood sample is collected, the study subject or 
guardian will be reminded that they are under no obligation to provide the sample and 
that they can withdraw from the study at any time. If permission is given this will be 
noted by the field assistant on a form. 
 
6. Subjects asked to join the longitudinal study in which nasopoharyngeal swabs will be 
collected will be asked to sign a separate consent form (Consent form 2)   
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MEDICAL RESEARCH COUNCIL (MRC)/GAMBIAN COMMUNITY 
PNEUMOCOCCAL CONJUGATE VACCINE TRIAL 
  
INFORMATION SHEET TO BE EXPLAINED TO PARENTS AND ADULT 
PARTICIPANTS 
 
Pneumonia, an infection of the lungs and meningitis an infection of the brain, 
are both serious diseases in The Gambia causing many deaths and much serious illness. 
These conditions are most frequent in young children but can also affect adults.  
 
The germs that cause pneumonia and meningitis are often found in the throat of people who 
are quite healthy but the germs can spread from these healthy people to other people who 
may then become seriously sick. The germs have many different types. MRC is working with 
the Government of The Gambia on the evaluation of vaccines to prevent some kinds of 
pneumonia and meningitis. A successful trial of a pneumonia vaccine was concluded in URD 
and CRD last year.   
 
MRC would want to know whether or not there would be changes in the types of this germ in 
the throat when the vaccine is used in a large scale in the future. You and members of your 
family are invited to take part in the study. 
  
All children up to the age of 30 months will receive 3 doses, at one monthly interval, of a 
pneumococcal vaccine that has been licensed and in use in the USA since year 2000 without 
any serious adverse effects. A group of older children and adults in 10 villages will also 
receive pneumococcal conjugate vaccine. A second group of older children and adults in 11 
villages will receive a single dose of meningococcal polysaccharide vaccine. 
  
We will place a thin cotton-tipped soft plastic swab into one of the nostrils to collect some 
secretions from the throat. This procedure is not painful and is not associated with any risk of 
injury. It will only cause mild and temporary discomfort to the person.  For most of the 
villagers it will be done only once.  For a number of persons it will be done a number of times 
and we will explain to the parents or participants before it is done. 
 
You and some members of your household will be asked to contribute a small volume of 
blood, about one spoonful (5 ml) and saliva when the swab is taken.  These samples will be 
tested for the presence of substances that can neutralize the activities of the germs.  
 
You and your family can withdraw from this study at any time. Participation in the study is 
entirely voluntary and will not interfere with standard healthcare that you and your family 
would normally receive or with their routine vaccination.   
 
Do you have any questions about the study? 
 
Do you agree to join the study? If you agree the consent form will be read to you before you 
sign the form. 
  
The field assistant will countersign the consent form to indicate the compound heads 
understood the explanation and freely gave their consent 
 
Contact information: If you require further information about the study, 
please contact the following people at the addresses shown below: 
 
1. Dr Richard Adegbola    2. Dr Uzochukwu Egere 
MRC Laboratories, Fajara        MRC Laboratories  
P O Box 273 Banjul. The Gambia      Phone: 7820343.  
Phone: 495442 (work)        
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Phone: 4496580 (home) 
Fax: 4495919  
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MEDICAL RESEARCH COUNCIL (MRC)/GAMBIAN COMMUNITY PNEUMOCOCCAL 
CONJUGATE VACCINE TRIAL 
 
CONSENT FORM 1 
 
Consent to join the trial- compound heads 
 
I understand that my family and I have been asked to take part in a trial of two vaccines that 
prevent meningitis and pneumonia.  I understand that if I agree to take part in the trial my 
family and I will receive one or other of these vaccines with 3 injections for young babies, 2 
for older children and 1 for adults. It has been explained to me that these vaccines have been 
given to many thousands of people and are safe but that they may cause a little pain where 
they are injected and a little fever.  I understand that if I agree for my family to be 
vaccinated then swabs may be collected from our throats using a small stick with wool on the 
end one to three times a year (three times in young babies).  Some members of the 
household will be asked to contribute a small volume of blood, about one spoonful (5 ml) and 
saliva before and after vaccination and subsequently at 3, 12 and 24 months after the 
completion of the first round of vaccination.  I understand that each person will be asked for 
his or her permission before a throat swab, saliva or blood sample is collected.  I understand 
that participation in the trial is entirely voluntary and will not interfere with standard 
healthcare that my family would normally receive or with their routine vaccination.  The study 
doctor and nurse field workers will provide free healthcare services to all study participants 
during the study period. I understand that I or any member of my family can leave the trial at 
any point without this interfering with their access to healthcare service if they become sick in 
any way. 
 
I have had an opportunity to ask the MRC field worker who explained the trial to me any 
questions that I had about the trial. 
 
I agree that my family and/or* I can join the study.  
 
Name……………………………………………………………………………………………………….. 
 
Signature or thumbprint 
 
____________________________________________________________________________ 
 
I, ………………………………………………………., confirm that I have explained the nature of the  
 
trial to……………………………………………………………. as set out in the study protocol (SOP no.), 
that s/he understood what I said, had an opportunity to ask questions and freely gave his/her 
consent for him/her and/or* his/her family to join the trial. 
 
NAME OF FIELD WORKER………………………………………………………………………………. 
 
SIGNATURE……………………………………………………………………………………………….. 
 
DATE  |__|__|/|__|__|/|__|__|__|__| 
 
and/or* = delete as appropriate 
 
Contact information: If you require further information about the study, please contact the 
following people at the addresses shown below: 
2. Dr Richard Adegbola    2. Dr Uzochukwu Egere 
MRC Laboratories, Fajara        MRC Laboratories  
P O Box 273 Banjul. The Gambia      Phone:7820343.  
Phone: 4495442 (work)        
Version 4: August 2006 23 
MEDICAL RESEARCH COUNCIL (MRC)/GAMBIAN COMMUNITY PNEUMOCOCCAL 
CONJUGATE VACCINE TRIAL 
 
CONSENT FORM 2 
 
Consent form for subjects from who repeated nasopharyngeal samples will be 
collected 
 
I have previously given my consent to be vaccinated with one or other of two vaccines that 
prevent meningitis and pneumonia.  I understand that I am now being asked to provide a 
number of samples from my throat to see the effects of the vaccine on the germs that cause 
these illnesses and that live in the throat during the next few years.  I understand that 
initially I will be asked to give a sample every month for 6 months and then 3 times a year for 
2 years. I understand that collecting these samples is a little uncomfortable but that it will not 
do any harm. It has been explained to me that I may withdraw from the study at any time.   
 
I have had an opportunity to ask any questions about what participation in the study will 
involve. 
 
I agree to join the study. 
 
Name ………………………………………………………………………………………………………. 
 
Signature or thumbprint 
 
____________________________________________________________________________
______ 
 
I, ………………………………………………………., confirm that I have explained the nature of the  
 
trial to……………………………………………………………. as set out in the study protocol (SOP no.), 
that s/he understood what I said, had an opportunity to ask questions and freely gave his/her 
consent for to join the trial. 
 
NAME OF FIELD WORKER………………………………………………………………………………. 
 
SIGNATURE……………………………………………………………………………………………….. 
 
DATE  |__|__|/|__|__|/|__|__|__|__| 
 
 
Contact information: If you require further information about the study, please contact the 
following people at the addresses shown below: 
 
3. Dr Richard Adegbola     2. Dr Uzochukwu Egere  
MRC Laboratories, Fajara         MRC Laboratories  
P O Box 273 Banjul. The Gambia        Phone: 7820343  
Phone: 4495442 (work)         
Phone: 4496580 (home) 
Fax: 4495919  
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MEDICAL RESEARCH COUNCIL (MRC)/GAMBIAN COMMUNITY PNEUMOCOCCAL 
CONJUGATE VACCINE TRIAL 
 
CONSENT FORM 3 
 
Consent to join the trial- children 
 
I understand   I have been asked to permit my child to take part in a trial of two vaccines that prevent 
meningitis and pneumonia.  I understand that if I agree to permit my child to take part in the trial my 
child will receive one or other of these vaccines with 3 injections for young babies and 2 for older 
children.   It has been explained to me that these vaccines have been given to many thousands of people 
and are safe but that they may cause a little pain where they are injected and a little fever.  I understand 
that if I agree for my child to be vaccinated then swabs may be collected from his/her throats using a 
small stick with wool on the end one to three times a year (three times in young babies).  I understand 
that my child may be asked to contribute a small volume of blood, about one spoonful (5 ml) and saliva 
before and after vaccination and subsequently at 3, 12 and 24 months after the completion of the first 
round of vaccination.  I understand that participation in the trial is entirely voluntary and will not 
interfere with standard healthcare that my family would normally receive or with their routine 
vaccination.  The study doctor and nurses will provide free healthcare services to all study participants 
during the study period. I understand that I or any member of my family can leave the trial at any point 
without this interfering with their access to healthcare service if they become sick in any way. 
 
I have had an opportunity to ask the MRC field worker who explained the trial to me and answers to 
any questions that I had about the trial. 
 
I agree that my child can join the study.  
 
Name……………………………………………………………………………………………………… 
 
Signature or thumbprint………………………………………………………………………………….. 
 
Subject ID of child………………………………………………………………………………………... 
 
__________________________________________________________________________________ 
 
I, ………………………………………………………., confirm that I have explained the nature of the  
 
trial to……………………………………………………………. as set out in the study protocol (SOP 
no.), that s/he understood what I said, had an opportunity to ask questions and freely gave his/her 
consent for him/her and/or* his/her family to join the trial. 
 
NAME OF FIELD 
WORKER………………………………………………………………………………. 
 
SIGNATURE……………………………………………………………………………………………
….. 
 
DATE  |__|__|/|__|__|/|__|__|__|__| 
 
 and/or* = delete as appropriate 
Contact information: If you require further information about the study, please contact the following 
people at the addresses shown below: 
Dr Richard Adegbola      Dr Uzochukwu Egere 
MRC Laboratories, Fajara         MRC Laboratories  
P O Box 273 Banjul. The Gambia       Phone: 7820343  
Phone: 495442 (work)       
Phone: 496580 (home) 
Fax: 495919  
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MEDICAL RESEARCH COUNCIL (MRC)/GAMBIAN COMMUNITY PNEUMOCOCCAL 
CONJUGATE VACCINE TRIAL 
 
CONSENT FORM 4 
 
Consent to join the trial- Adults  
 
I understand that   I have been asked to take part in a trial of two vaccines that prevent meningitis and 
pneumonia.  I understand that if I agree to take part in the trial I will receive a dose of one or other of 
these vaccines. It has been explained to me that these vaccines have been given to many thousands of 
people and are safe but that they may cause a little pain where they are injected and a little fever.  I 
understand that if I agree   to be vaccinated then swabs may be collected from our throats using a small 
stick with wool on the end one to three times a year. I understand that I may be asked to contribute a 
small volume of blood, about one spoonful (5 ml) and saliva before and after vaccination and 
subsequently at 3, 12 and 24 months after the completion of the first round of vaccination. I understand 
that participation in the trial is entirely voluntary and will not interfere with standard healthcare that I 
would normally receive.  The study doctor and nurses will provide free healthcare services to all study 
participants during the study period. I understand that I can leave the trial at any point without this 
interfering with my access to healthcare service if I become sick in any way. 
 
I have had an opportunity to ask the MRC field worker who explained the trial to me and answers to 
questions that I had about the trial. 
 
I agree  to join the study.  
 
Name……………………………………………………………………………………………………… 
 
Subject ID………………………………………………………………………………………………… 
 
Signature or thumbprint 
 
__________________________________________________________________________________ 
 
I, ………………………………………………………., confirm that I have explained the nature of the  
 
trial to……………………………………………………………. as set out in the study protocol (SOP 
no.), that s/he understood what I said, had an opportunity to ask questions and freely gave his/her 
consent for him/her and/or* his/her family to join the trial. 
 
NAME OF FIELD 
WORKER………………………………………………………………………………. 
 
SIGNATURE……………………………………………………………………………………………
….. 
 
DATE  |__|__|/|__|__|/|__|__|__|__| 
 
and/or* = delete as appropriate 
 
Contact information: If you require further information about the study, please contact the following 
people at the addresses shown below: 
Dr Richard Adegbola       Dr Uzochukwu Egere 
MRC Laboratories, Fajara         MRC Laboratories  
P O Box 273 Banjul. The Gambia       Phone: 7820343  
Phone: 495442 (work)       
Phone: 496580 (home) 
Fax: 495919  
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